Baseline characteristics for patients undergoing allo-HCT for MF from 2000 to 2016, who were included in the CIBMTR and EBMT cohorts
| Variable . | CIBMTR . | EBMT . | P value . |
|---|---|---|---|
| No. of patients | 623 | 623 | |
| Median follow-up of survivors (range), mo | 42 (3-193) | 83 (3-219) | |
| Patient related | |||
| Age at diagnosis, median (range), y | 54 (40-75) | 52 (40-74) | <.01† |
| Age at HCT, median (range), y | 58 (40-76) | 57 (41-74) | <.01† |
| Sex | .12‡ | ||
| Male | 395 (63%) | 421 (68%) | |
| Karnofsky performance status score before HCT | <.01‡ | ||
| 90-100 | 373 (60%) | 313 (50%) | |
| HCT-CI | <.01‡ | ||
| 0 | 113 (18%) | 201 (32%) | |
| 1 | 62 (10%) | 53 (9%) | |
| 2 | 67 (11%) | 41 (7%) | |
| 3+ | 174 (28%) | 84 (13%) | |
| Disease related | |||
| Disease at diagnosis | <.01‡ | ||
| MF | 542 (87%) | 499 (80%) | |
| Polycythemia vera | 32 (5%) | 52 (8%) | |
| Essential thrombocythemia | 49 (8%) | 52 (8%) | |
| Polycythemia vera/essential thrombocythemia | 20 (3%) | ||
| Blast in peripheral blood of >1% at diagnosis | 89 (14%) | 104 (17%) | .09‡ |
| Hemoglobin level <100 g/L at diagnosis | 216 (35%) | 214 (34%) | <.01‡ |
| WBC count >25 × 109/L at diagnosis | 59 (9%) | 49 (8%) | <.01‡ |
| Platelet count at diagnosis, 50 × 109/L–100 × 109/L | 80 (13%) | 87 (14%) | <.01‡ |
| Constitutional symptoms at diagnosis | 183 (29%) | 176 (28%) | <.01‡ |
| Blast in peripheral blood >1% before HCT | 188 (30%) | 200 (32%) | <.01‡ |
| Hemoglobin level <100 g/L before HCT | 442 (71%) | 411 (66%) | .06‡ |
| WBC count >25 × 109/L before HCT | 82 (13%) | 95 (15%) | <.01‡ |
| Platelet count 50 × 109/L–100 × 109/L before HCT | 133 (21%) | 107 (17%) | <.01‡ |
| Constitutional symptoms before HCT | 104 (17%) | 181 (29%) | <.01‡ |
| DIPSS before HCT | |||
| Low | 76 (12%) | ||
| Intermediate-1 | 283 (45%) | ||
| Intermediate-2 | 236 (38%) | ||
| High | 11 (2%) | ||
| Cytogenetics | |||
| Favorable (normal) | 251 (40%) | ||
| Favorable (other) | 113 (18%) | ||
| Unfavorable | 113 (18%) | ||
| Not tested | 34 (5%) | ||
| JAK2 mutation | <.01‡ | ||
| Yes | 202 (32%) | 213 (34%) | |
| Spleen status | <.01‡ | ||
| Normal | 132 (21%) | 81 (13%) | |
| Splenomegaly | 451 (72%) | 304 (49%) | |
| Splenectomy | 23 (4%) | 90 (14%) | |
| Treatment-related, nontransplantation | |||
| Prior therapy | <.01‡ | ||
| Yes | 468 (75%) | 340 (55%) | |
| Missing | 4 (1%) | 55 (9%) | |
| Number of lines of pretreatments | <.01‡ | ||
| 0 | 151 (24%) | 228 (37%) | |
| 1 | 255 (41%) | 126 (20%) | |
| 2 | 108 (17%) | 18 (3%) | |
| ≥3 | 101 (16%) | 16 (3%) | |
| Received Jakafi as prior therapy | <.01‡ | ||
| Yes | 175 (28%) | 85 (14%) | |
| Treatment-related, transplantation | |||
| Time from diagnosis to HCT (mo) | 18 (2-294) | 26 (2-268) | <.01† |
| Donor type | <.01‡ | ||
| HLA-identical sibling | 221 (35%) | 469 (75%) | |
| Well-matched unrelated | 322 (52%) | 107 (17%) | |
| Partially matched unrelated | 80 (13%) | 47 (8%) | |
| Sex match of donor and recipient | .04‡ | ||
| M-M | 257 (41%) | 253 (41%) | |
| M-F | 134 (22%) | 168 (27%) | |
| F-M | 136 (22%) | 107 (17%) | |
| F-F | 93 (15%) | 95 (15%) | |
| Graft source | .58‡ | ||
| Peripheral blood | 554 (89%) | 560 (90%) | |
| Use of TBI | .59‡ | ||
| No | 526 (84%) | 530 (85%) | |
| Conditioning regimen intensity | <.01‡ | ||
| MAC | 285 (46%) | 181 (29%) | |
| RIC | 292 (47%) | 440 (71%) | |
| NMA | 37 (6%) | ||
| GVHD prophylaxis | <.01‡ | ||
| Post-CY + other(s) | 9 (1%) | 14 (2%) | |
| TAC + MMF ± other(s) (except post-CY) | 88 (14%) | 3 (0) | |
| TAC + MTX ± other(s) (except MMF, post-CY) | 281 (45%) | 6 (1%) | |
| TAC + other(s) (except MMF, MTX, post-CY) | 32 (5%) | 7 (1%) | |
| TAC alone | 11 (2%) | 3 (0) | |
| CSA + MMF ± other(s) (except post-CY) | 63 (10%) | 193 (31%) | |
| CSA + MTX ± other(s) (except MMF, post-CY) | 111 (18%) | 258 (41%) | |
| CSA + other(s) (except MMF, MTX, post-CY) | 6 (1%) | 15 (2%) | |
| CSA alone | 12 (2%) | 82 (13%) | |
| Other(s) | 8 (1%) | 15 (2%) | |
| Median follow-up of survivors (range), mo | 42 (3-193) | 83 (3-219) |
| Variable . | CIBMTR . | EBMT . | P value . |
|---|---|---|---|
| No. of patients | 623 | 623 | |
| Median follow-up of survivors (range), mo | 42 (3-193) | 83 (3-219) | |
| Patient related | |||
| Age at diagnosis, median (range), y | 54 (40-75) | 52 (40-74) | <.01† |
| Age at HCT, median (range), y | 58 (40-76) | 57 (41-74) | <.01† |
| Sex | .12‡ | ||
| Male | 395 (63%) | 421 (68%) | |
| Karnofsky performance status score before HCT | <.01‡ | ||
| 90-100 | 373 (60%) | 313 (50%) | |
| HCT-CI | <.01‡ | ||
| 0 | 113 (18%) | 201 (32%) | |
| 1 | 62 (10%) | 53 (9%) | |
| 2 | 67 (11%) | 41 (7%) | |
| 3+ | 174 (28%) | 84 (13%) | |
| Disease related | |||
| Disease at diagnosis | <.01‡ | ||
| MF | 542 (87%) | 499 (80%) | |
| Polycythemia vera | 32 (5%) | 52 (8%) | |
| Essential thrombocythemia | 49 (8%) | 52 (8%) | |
| Polycythemia vera/essential thrombocythemia | 20 (3%) | ||
| Blast in peripheral blood of >1% at diagnosis | 89 (14%) | 104 (17%) | .09‡ |
| Hemoglobin level <100 g/L at diagnosis | 216 (35%) | 214 (34%) | <.01‡ |
| WBC count >25 × 109/L at diagnosis | 59 (9%) | 49 (8%) | <.01‡ |
| Platelet count at diagnosis, 50 × 109/L–100 × 109/L | 80 (13%) | 87 (14%) | <.01‡ |
| Constitutional symptoms at diagnosis | 183 (29%) | 176 (28%) | <.01‡ |
| Blast in peripheral blood >1% before HCT | 188 (30%) | 200 (32%) | <.01‡ |
| Hemoglobin level <100 g/L before HCT | 442 (71%) | 411 (66%) | .06‡ |
| WBC count >25 × 109/L before HCT | 82 (13%) | 95 (15%) | <.01‡ |
| Platelet count 50 × 109/L–100 × 109/L before HCT | 133 (21%) | 107 (17%) | <.01‡ |
| Constitutional symptoms before HCT | 104 (17%) | 181 (29%) | <.01‡ |
| DIPSS before HCT | |||
| Low | 76 (12%) | ||
| Intermediate-1 | 283 (45%) | ||
| Intermediate-2 | 236 (38%) | ||
| High | 11 (2%) | ||
| Cytogenetics | |||
| Favorable (normal) | 251 (40%) | ||
| Favorable (other) | 113 (18%) | ||
| Unfavorable | 113 (18%) | ||
| Not tested | 34 (5%) | ||
| JAK2 mutation | <.01‡ | ||
| Yes | 202 (32%) | 213 (34%) | |
| Spleen status | <.01‡ | ||
| Normal | 132 (21%) | 81 (13%) | |
| Splenomegaly | 451 (72%) | 304 (49%) | |
| Splenectomy | 23 (4%) | 90 (14%) | |
| Treatment-related, nontransplantation | |||
| Prior therapy | <.01‡ | ||
| Yes | 468 (75%) | 340 (55%) | |
| Missing | 4 (1%) | 55 (9%) | |
| Number of lines of pretreatments | <.01‡ | ||
| 0 | 151 (24%) | 228 (37%) | |
| 1 | 255 (41%) | 126 (20%) | |
| 2 | 108 (17%) | 18 (3%) | |
| ≥3 | 101 (16%) | 16 (3%) | |
| Received Jakafi as prior therapy | <.01‡ | ||
| Yes | 175 (28%) | 85 (14%) | |
| Treatment-related, transplantation | |||
| Time from diagnosis to HCT (mo) | 18 (2-294) | 26 (2-268) | <.01† |
| Donor type | <.01‡ | ||
| HLA-identical sibling | 221 (35%) | 469 (75%) | |
| Well-matched unrelated | 322 (52%) | 107 (17%) | |
| Partially matched unrelated | 80 (13%) | 47 (8%) | |
| Sex match of donor and recipient | .04‡ | ||
| M-M | 257 (41%) | 253 (41%) | |
| M-F | 134 (22%) | 168 (27%) | |
| F-M | 136 (22%) | 107 (17%) | |
| F-F | 93 (15%) | 95 (15%) | |
| Graft source | .58‡ | ||
| Peripheral blood | 554 (89%) | 560 (90%) | |
| Use of TBI | .59‡ | ||
| No | 526 (84%) | 530 (85%) | |
| Conditioning regimen intensity | <.01‡ | ||
| MAC | 285 (46%) | 181 (29%) | |
| RIC | 292 (47%) | 440 (71%) | |
| NMA | 37 (6%) | ||
| GVHD prophylaxis | <.01‡ | ||
| Post-CY + other(s) | 9 (1%) | 14 (2%) | |
| TAC + MMF ± other(s) (except post-CY) | 88 (14%) | 3 (0) | |
| TAC + MTX ± other(s) (except MMF, post-CY) | 281 (45%) | 6 (1%) | |
| TAC + other(s) (except MMF, MTX, post-CY) | 32 (5%) | 7 (1%) | |
| TAC alone | 11 (2%) | 3 (0) | |
| CSA + MMF ± other(s) (except post-CY) | 63 (10%) | 193 (31%) | |
| CSA + MTX ± other(s) (except MMF, post-CY) | 111 (18%) | 258 (41%) | |
| CSA + other(s) (except MMF, MTX, post-CY) | 6 (1%) | 15 (2%) | |
| CSA alone | 12 (2%) | 82 (13%) | |
| Other(s) | 8 (1%) | 15 (2%) | |
| Median follow-up of survivors (range), mo | 42 (3-193) | 83 (3-219) |
Nonmodifiable variables are indicated in italic.
CSA, cyclosporine; Cy, cyclophosphamide; HCT-CI, HCT-specific comorbidity index; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MTX, methotrexate; NMA, nonmyeloablative; RIC, reduced intensity conditioning; TAC, tacrolimus; TBI, total body irradiation; WBC, white blood cell.
∗Missing data are presented in the supplemental Tables.
Kruskal Wallis test.
Pearson χ2 test.